Evidence map›Paper›PMID 39286886›Full record

ArticleClinical and translational allergy2024

The impact of COVID-19 on hay fever treatment in Japan: A retrospective cohort study based on the Japanese claims database.

Yasutsugu Akasaki, Takenori Inomata, Masao Iwagami, Jaemyoung Sung, Ken Nagino, Takeya Adachi, Hideaki Morita, Mayumi Tamari, Keigo Kainuma, Keiko Kan-O and 18 more

Abstract read
In one paragraph

Article in Clinical and translational allergy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Yasutsugu AkasakiDepartment of Ophthalmology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Takenori InomataDepartment of Ophthalmology, Juntendo University Graduate School of Medicine, Tokyo, Japan.ORCID https://orcid.org/0000-0003-3435-1055
Masao IwagamiDepartment of Health Services Research, Institute of Medicine, University of Tsukuba, Ibaraki, Japan.
Jaemyoung SungDepartment of Ophthalmology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Ken NaginoDepartment of Ophthalmology, Juntendo University Graduate School of Medicine, Tokyo, Japan.ORCID https://orcid.org/0000-0002-0317-6074
Takeya AdachiENGAGE-Task Force, Tokyo, Japan.
Hideaki MoritaENGAGE-Task Force, Tokyo, Japan.
Mayumi TamariENGAGE-Task Force, Tokyo, Japan.
Keigo KainumaENGAGE-Task Force, Tokyo, Japan.
Keiko Kan-OENGAGE-Task Force, Tokyo, Japan.
Hiroaki OgataENGAGE-Task Force, Tokyo, Japan.
Masafumi SakashitaENGAGE-Task Force, Tokyo, Japan.
Masaki FutamuraENGAGE-Task Force, Tokyo, Japan.
Yosuke KurashimaENGAGE-Task Force, Tokyo, Japan.
Saeko NakajimaENGAGE-Task Force, Tokyo, Japan.
Katsunori MasakiENGAGE-Task Force, Tokyo, Japan.
Yasushi OgawaENGAGE-Task Force, Tokyo, Japan.
Sakura SatoENGAGE-Task Force, Tokyo, Japan.ORCID https://orcid.org/0000-0003-3674-0759
Akihiro MiyagawaDepartment of Dermatology, Keio University School of Medicine, Tokyo, Japan.
Akie Midorikawa-InomataDepartment of Hospital Administration, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Keiichi FujimotoDepartment of Ophthalmology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Yuichi OkumuraDepartment of Ophthalmology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Kenta FujioDepartment of Ophthalmology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Tianxiang HuangDepartment of Ophthalmology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Kunihiko HirosawaDepartment of Ophthalmology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Yuki MorookaDepartment of Ophthalmology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Akira MurakamiDepartment of Ophthalmology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Shintaro NakaoDepartment of Ophthalmology, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Funding

Health, Labor and Welfare Sciences Research Grant 21FE2001Ichiro Kanehara Foundation for the Promotion of Medical Sciences and Medical CareJapan Agency for Medical Research and Development 21ek0410063h003Japan Agency for Medical Research and Development 24ek0410090h0003Nishikawa Medical FoundationOver-the-counter Drug Self-Medication Promotion FoundationThe Institute for Environmental & Gender-specific Medicine, Juntendo UniversityThe Kondou Kinen Medical Foundation
6 · The paper itself

Abstract

backgroundHay fever (HF) presents with various symptoms, including allergic conjunctivitis and rhinitis, and requires cross-organ treatment. This study assessed the impact of the coronavirus disease 2019 (COVID-19) pandemic on HF treatment trends.

methodsThis retrospective cohort study utilized data from the JMDC database collected between January 2018 and May 2021. Patients with HF were identified based on the relevant International Classification of Diseases 10th Revision diagnosis codes and the prescription of HF-related medications. The treatment approaches were compared during the cedar and cypress pollen allergy season (January to May in Japan) before and during the COVID-19 pandemic (2018 and 2019, and 2020 and 2021, respectively).

resultsThis study included 2,598,178 patients with HF. The numbers of prescribed HF-related claims in 2018, 2019, 2020, and 2021 were 3,332,854, 3,534,198, 2,774,380, and 2,786,681 times, respectively. Oral second-generation antihistamine prescriptions decreased by >10% from 2019 to 2020, with a <10% change in the subsequent year. Anti-allergic eye drop prescriptions also decreased by >10% from 2019 to 2020 but increased by >10% from 2020 to 2021. Compared with 2018, 2019, and 2020, the number of claims in the rhinitis symptoms dominant group was significantly decreased in 2021 (p < 0.001, all). In contrast, the number of claims in the eye symptoms dominant group and the rhinitis and eye symptoms dominant group increased in 2021 compared with that in 2018, 2019, and 2020 (p < 0.001, all).

conclusionChanges in HF treatment and related outcomes could be attributed to lifestyle modifications resulting from the COVID-19 pandemic. Measures, such as limiting outdoor activities and adopting mask-wearing practices may have influenced HF symptoms, preventive behaviors, and the overall approach to treating HF.

Indexed as

allergic conjunctivitisallergic rhinitisCOVID‐19hay feverSARS‐CoV‐2

Identifiers

PMID39286886
PMCPMC11406147

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.